IDH2 and central nervous system cancer: Despite its association with lower-grade gliomas, IDH mutations are often observed in secondary GBM (73%) as well [120], suggesting that lower-grade IDH-mutant gliomas are prone to malignant progression and recurrence as higher-grade gliomas [121].